Early and late therapy response assessment with [18F] fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: Analysis of a prospective multicenter trial

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages 4385-4391

  Furth, Christian ^a   Steffen, Ingo G ^a   Amthauer, Holger ^a   Ruf, Juri ^a   Misch, Daniel ^a   Schönberger, Stefan ^a   Kobe, Carsten ^a   Denecke, Timm ^a   Stöver, Brigitte ^a   Hautzel, Hubertus ^a   Henze, Günter ^a   Hundsdoerfer, Patrick ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHILD; CHILD CARE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TREATMENT RESPONSE; METHODOLOGY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TIME;

ADOLESCENT; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 70349317256     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.7814     Document Type: Article

References (40)

1. Korholz D, Claviez A, Hasenclever D, et al: The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: Evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 216:150-156, 2004
2. Ruhl U, Korholz D, Claviez A, et al: Responseadapted radiotherapy in the treatment of pediatric Hodgkin's disease: An interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 51:1209-1218, 2001
3. Dörffel W, Lüders H, Rühl U, et al: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr 215: 139-145, 2003
4. Korholz D, Kluge R, Wickmann L, et al: Importance of F18-fluorodeoxy-D-2- glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence: Consequences for the GPOH-HD 2003 protocol. Onkologie 26:489-493, 2003
5. Bhatia S, Robinson LL, Oberlin O, et al: Breast cancer and other second neoplasm after childhood Hodgkin's disease. N Engl J Med 334:745-751, 1996
6. Bhatia S, Yasui Y, Robinson LL, et al: High risk of subsequent neoplasm continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol 23:4386-4394, 2003
7. Foss-Abrahamsen A, Andersen A, Nome O, et al: Long-term risk of second malignancy after treatment of Hodgkin's disease: The influence of treatment, age and follow-up time. Ann Oncol 13: 1786-1791, 2002
8. van Leeuwen FE, Klokman WJ, Veer MB, et al: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18:487-497, 2000
9. Green DM, Hyland A, Barcos MP, et al: Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol, 18:1492-1499, 2000
10. Schellong G, Riepenhausen M: Late effects after therapy of Hodgkin's disease: Update 2003/04 on overwhelming post-splenectomy infections and secondary malignancies. Klin Padiatr 216:364-369, 2004
11. Juweid ME: Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 259- 65:510-511, 2006
12. Juweid ME, Strootbants S, Hoekstra OS, et al: Imaging Subcommittee of International Harmonization Project in Lymphoma: Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578, 2007
13. Hutchings M, Mikhaeel NG, Fields PA, et al: Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160-1168, 2005
14. Hutchings M, Loft A, Hansen M, et al: FDGPET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
15. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007
16. Kostakoglu L, Goldsmith SJ, Leonard JP, et al: FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107:2678-2687, 2006
17. Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002
18. Mikhaeel NG, Hutchings M, Fields PA, et al: FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in highgrade non-Hodgkin lymphoma. Ann Oncol 16:1514-1523, 2005
19. Levine JM, Weiner M, Kelly KM: Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 28:711-714, 2006
20. Meany HJ, Gidvani VK, Minniti CP: Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 48:399-402, 2007
21. Miller E, Metser U, Avrahami G, et al: Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 30:689-694, 2006
22. 18F]FDG in childhood lymphoma: Clinical utility and impact on management. Eur J Nucl Med Mol Imaging 29:1155-1165, 2002
23. Rhodes MM, Delbeke D, Whitlock JA, et al: Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 28:300-306, 2006
24. Furth C, Denecke T, Steffen I, et al: Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease J Pediatr Hematol Oncol 28:501-512, 2006
25. Sobin LH, Wittekind C: TNM Classification of Malignant Tumours. New York, NY, John Wiley & Sons, 2002
26. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
27. Bennett BM: On comparisons of sensitivity, specificity and predictive value of a number of diagnostic procedures. Biometrics 28:793-800, 1972
28. Cohade C, Mourtzikos KA, Wahl RL: "USAFat": Prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. J Nucl Med 44:1267-1270, 2003
29. Hernandez-Pampaloni M, Takalkar A, Yu JQ, et al: F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 36:524-531, 2006
30. Torizuka T, Nakamura F, Kanno T, et al: Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 31:22-28, 2004
31. Di Cesare E, Cerone G, Enrici RM, et al: MRI characterization of residual mediastinal masses in Hodgkin's disease: Long-term follow-up. Magn Reson Imaging 22:31-38, 2004
32. Jerusalem G, Beguin Y, Fassotte MF, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999
33. Schelling M, Avril N, Nährig J, et al: Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000
34. Weber WA, Ott K, Becker K, et al: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065, 2001
35. Hoekstra CJ, Stroobants SG, Smit EF, et al: Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced nonsmall-cell lung cancer. J Clin Oncol 23:8362-8370, 2005
36. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998
37. Zinzani PL, Tani M, Fanti S, et al: Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients. Ann Oncol 17:1296-1300, 2006
38. Castellucci P, Zinzani P, Pourdehnad M, et al: 18F-FDG PET in malignant lymphoma: Significance of positive findings. Eur J Nucl Med Mol Imaging 32:749-756, 2005
39. Haioun C, Itti E, Rahmouni A, et al: [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 106:1376-1381, 2005
40. Gallamini A, Rigacci L, Merli F, et al: The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91:475-481, 2006